Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B |
| Cost of Revenue | $377.72M | $315.15M | $253.35M | $187.34M | $161.63M | $147.28M | $127.59M | $110.16M |
| Gross Profit | $3.86B | $3.38B | $3.14B | $2.80B | $2.51B | $2.01B | $1.75B | $1.43B |
| Gross Margin | 91.09% | 91.47% | 92.54% | 93.73% | 93.94% | 93.18% | 93.22% | 92.83% |
| Operating Expenses | $3.78B | $2.73B | $2.54B | $2.16B | $2.75B | $1.59B | $1.60B | $1.66B |
| Operating Income | $80.14M | $651.77M | $599.56M | $637.54M | $-240.29M | $421.69M | $155.40M | $-235.68M |
| Operating Margin | 1.89% | 17.64% | 17.66% | 21.35% | -9.01% | 19.53% | 8.26% | -15.34% |
| Net Income | $32.62M | $597.60M | $340.66M | $948.58M | $-295.70M | $446.91M | $109.49M | $-313.14M |
| Net Margin | 0.77% | 16.17% | 10.04% | 31.76% | -11.09% | 20.70% | 5.82% | -20.38% |
| EPS (Basic) | $0.16 | $2.67 | $1.53 | $4.30 | $-1.36 | $2.08 | $0.52 | $-1.53 |
| EBITDA | $408.16M | $919.43M | $599.64M | $630.20M | $-178.24M | $543.18M | $171.86M | $-253.21M |
| Stock Option Compensation Expense | $266.06M | $215.89M | $188.42M | $183.01M | $177.88M | $166.59M | $148.15M | $133.06M |
| Price To Earnings Ratio | 438.60 | 23.50 | 52.34 | 17.06 | -64.15 | 41.99 | 123.35 | -61.88 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $14.31B | $14.04B | $17.83B | $16.18B | $18.97B | $18.77B | $13.51B | $19.38B |